Sept 20 (Reuters) - Mirati Therapeutics Inc named
industry veteran David Meek as its chief executive officer on
Monday as it pushes on with the development of its promising
candidates for cancer treatment.
58-year-old Meek will join the company's board and replaces
Charles Baum, who has served as the president and CEO of
California-based Mirati since 2012.
Meek most recently headed gene-therapy company FerGene,
which was launched in 2019 by Swiss drugmaker Ferring
Pharmaceuticals and investment firm Blackstone Life Sciences.
He has also held leadership roles at other pharmaceutical
and biotechnology companies such as French firm Ipsen, Baxalta
and Novartis Pharma.
Mirati has focused on developing cancer treatments and its
two lead candidates - adagrasib and sitravatinib - are in
"I am confident in David's abilities to lead Mirati through
its next chapter as we bring adagrasib, sitravatinib and other
novel oncology therapeutics to patients," said Baum, who will
continue to head the company's R&D division and stay on its
Separately, Mirati said adagrasib - which targets a mutated
form of the KRAS gene - had shown a high rate of responses in a
small study of patients with advanced lung cancer.
The drug showed an objective response rate of 43% and a
disease control rate of 80% in the study.
The drug developer said on Sunday adagrasib in combination
with older cancer drug Erbitux shrank tumors in 39% of patients
with advanced colorectal cancer treated in a small trial.
Mirati expects to submit a marketing application for
adagrasib with the U.S. drug regulator in the fourth quarter of
(Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya